Myriad Genetics, Inc. (MYGN)
| Previous Close | 19.26 |
| Open | 19.26 |
| Bid | 19.50 x 800 |
| Ask | 19.53 x 1000 |
| Day's Range | 19.11 - 19.81 |
| 52 Week Range | 13.92 - 28.18 |
| Volume | |
| Avg. Volume | 762,826 |
| Market Cap | 1.576B |
| Beta (5Y Monthly) | 1.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings Date | Nov 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.56 |
- Zacks
Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
- GlobeNewswire
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
Myriad Genetics continues to advance non-invasive prenatal screening with Prequel® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the clinical value of non-invasive prenatal screening (NIPS) for a range of chr
- GlobeNewswire
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be available through a live webcast on the Myriad Genetics Investor Relations website. An archive
